Medecine et maladies infectieuses最新文献

{"title":"Flu vaccine coverage for recommended populations in France","authors":"J. Robert ,&nbsp;B. Detournay ,&nbsp;M.C. Levant ,&nbsp;M. Uhart ,&nbsp;J. Gourmelen ,&nbsp;J.M. Cohen","doi":"10.1016/j.medmal.2019.12.004","DOIUrl":"10.1016/j.medmal.2019.12.004","url":null,"abstract":"<div><h3>Objectives</h3><p>To estimate the size of the populations targeted by the French recommendations of the High Council for Public Health (French acronym HCSP) regarding vaccination against seasonal flu and to estimate vaccination coverage rates in these populations.</p></div><div><h3>Patients and methods</h3><p>The analysis was conducted on a representative sample of patients retrieved from the French Health Insurance databases during three influenza seasons (2012–2013, 2013–2014, 2014–2015). Patients targeted by the influenza vaccination recommendations were identified based on their sociodemographic characteristics and disease identification algorithms during each season. Vaccine coverage rates were estimated based on reimbursed influenza vaccines. Results were extrapolated using indirect standardization to the overall French population.</p></div><div><h3>Results</h3><p>Populations targeted by the recommendations were estimated after extrapolation to 17.6, 17.8, and 18.0 million for the 2012–13, 2013–14, and 2014–15 influenza seasons, respectively. The vaccination coverage rates in these target populations were respectively estimated at 32.1%, 31.9%, and 32.1%; i.e. 44.2%, 43.1%, and 42.7% for individuals aged ≥<!--> <!-->65 years and 12.9%, 13.2%, and 13.7% for individuals ˂<!--> <!-->65 years of age presenting a risk justifying vaccination.</p></div><div><h3>Conclusions</h3><p>Immunization coverage against influenza in France remains well below the target of 75% set by the World Health Organization. Multiple strategies combining communication, education, access program, and professional engagement could be implemented to improve this situation.</p></div>","PeriodicalId":18464,"journal":{"name":"Medecine et maladies infectieuses","volume":"50 8","pages":"Pages 670-675"},"PeriodicalIF":5.0,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.medmal.2019.12.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37509211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kaposi's sarcoma associated with Good syndrome","authors":"M. Chastagner ,&nbsp;F. Durupt ,&nbsp;J. Hicks ,&nbsp;A. Bruyas ,&nbsp;P. Sève ,&nbsp;Y. Jamilloux","doi":"10.1016/j.medmal.2020.07.006","DOIUrl":"10.1016/j.medmal.2020.07.006","url":null,"abstract":"","PeriodicalId":18464,"journal":{"name":"Medecine et maladies infectieuses","volume":"50 8","pages":"Pages 752-754"},"PeriodicalIF":5.0,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.medmal.2020.07.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38249823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PK/PD targets of amikacin and gentamicin in ICU patients","authors":"A. Coste ,&nbsp;G. Deslandes ,&nbsp;L. Jalin ,&nbsp;S. Corvec ,&nbsp;J. Caillon ,&nbsp;D. Boutoille ,&nbsp;M. Grégoire ,&nbsp;C. Bretonnière","doi":"10.1016/j.medmal.2019.12.003","DOIUrl":"10.1016/j.medmal.2019.12.003","url":null,"abstract":"<div><h3>Objectives</h3><p>We aimed to evaluate the probability to achieve PK-PD targets in patients with sepsis hospitalized in the intensive care unit (ICU) after a single dose of 30<!--> <!-->mg/kg of amikacin or 8<!--> <!-->mg/kg of gentamicin.</p></div><div><h3>Patients and methods</h3><p>This single-center prospective study included 138 ICU patients with severe sepsis or septic shock with an indication for intravenous amikacin (<em>N</em> <!-->=<!--> <!-->89) or gentamicin (<em>N</em> <!-->=<!--> <!-->49). Maximum concentration (C_max) was measured 30 minutes after infusion completion. PK/PD objectives were respectively C_max <!-->≥<!--> <!-->60<!--> <!-->mg/L and ≥<!--> <!-->30<!--> <!-->mg/L for amikacin and gentamicin for empirical therapy, and a C_max/MIC ratio<!--> <!-->≥<!--> <!-->8, as per French guidelines.</p></div><div><h3>Results</h3><p>The median Simplified Acute Physiology Score II was 43 and ICU case fatality rate was 34.8%. A causative bacterial agent was identified in 94 patients (68.1%). Three pathogens had acquired aminoglycoside resistance and 15 were naturally resistant. The targeted C_max for the first dose was achieved in 53 patients (59.6%) receiving amikacin, and one (2.2%) patient receiving gentamicin. C_max/MIC ratio<!--> <!-->≥<!--> <!-->8 was obtained in all patients infected with susceptible pathogens (<em>N</em> <!-->=<!--> <!-->72). Factors associated with C_max <!-->≥<!--> <!-->60<!--> <!-->mg/L of amikacin in multivariate analysis were dose per kg of adapted body weight (OR<!--> <!-->=<!--> <!-->1.39, <em>P</em> <!-->&lt;<!--> <!-->0.001) and renal clearance estimated with CKD-EPI formula (OR<!--> <!-->=<!--> <!-->0.98, <em>P</em> <!-->=<!--> <!-->0.003).</p></div><div><h3>Conclusions</h3><p>Despite high doses, amikacin and gentamicin first C_max remain dramatically low in ICU patients. However, an adequate C_max/MIC ratio was reached in all patients.</p></div>","PeriodicalId":18464,"journal":{"name":"Medecine et maladies infectieuses","volume":"50 8","pages":"Pages 709-714"},"PeriodicalIF":5.0,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.medmal.2019.12.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37496785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cerebral phaeohyphomycosis in an immunocompetent patient","authors":"X.-C. Tong ,&nbsp;Y.-L. Qiu ,&nbsp;H.-W. Wang ,&nbsp;F.-R. Tan ,&nbsp;S.-Q. Ben ,&nbsp;T.-M. Xu","doi":"10.1016/j.medmal.2020.09.002","DOIUrl":"10.1016/j.medmal.2020.09.002","url":null,"abstract":"","PeriodicalId":18464,"journal":{"name":"Medecine et maladies infectieuses","volume":"50 8","pages":"Pages 756-758"},"PeriodicalIF":5.0,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.medmal.2020.09.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38456823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Compliance with antibiotic guidelines by urologists","authors":"M. Vallée ,&nbsp;F. Bruyère ,&nbsp;E. Bey ,&nbsp;C. Duran ,&nbsp;C. Le Goux ,&nbsp;A. Sotto ,&nbsp;A. Dinh ,&nbsp;the French infectious disease Committee of the Association Française d’Urologie (CIAFU)","doi":"10.1016/j.medmal.2020.09.003","DOIUrl":"10.1016/j.medmal.2020.09.003","url":null,"abstract":"","PeriodicalId":18464,"journal":{"name":"Medecine et maladies infectieuses","volume":"50 8","pages":"Pages 758-760"},"PeriodicalIF":5.0,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.medmal.2020.09.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38456824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Parathyroid gland hyperplasia associated with tuberculous granulomatous inflammation manifesting as primary hyperparathyroidism","authors":"M. Mayo-Yáñez ,&nbsp;F.J. Lage-Fernández ,&nbsp;L. López-Solache ,&nbsp;P. Parente-Arias","doi":"10.1016/j.medmal.2020.07.002","DOIUrl":"10.1016/j.medmal.2020.07.002","url":null,"abstract":"<div><h3>Objectives</h3><p>Inflammatory disorders of the parathyroid gland are poorly defined. Only seven cases of granulomatous infection have been reported in the literature.</p></div><div><h3>Patients and methods</h3><p>A 68-year-old woman presented with parathyroid hormone level at 277<!--> <!-->pg/mL and calcium level at 10.8<!--> <!-->mg/dL, considered as primary hyperparathyroidism. Parathyroidectomy was performed, normalizing analytical values.</p></div><div><h3>Results</h3><p>Normal-size gland with chief cell hyperplasia, focal pseudofollicular changes, and presence of epithelioid granulomas with Langhans giant cells and caseous necrosis areas, and a positive PCR for <em>M. tuberculosis</em> complex was identified. Chronic granulomatous inflammation could provoke a cascade of immune system activation, resulting in hyperplasia with the consequent increase in parathyroid function, and therefore primary hyperparathyroidism.</p></div><div><h3>Conclusions</h3><p>In populations with a high incidence of tuberculosis, the coexistence of these pathologies must be kept in mind. This theory needs further biomolecular studies to be confirmed, but it provides a new perspective within the possible etiologies of hyperparathyroidism.</p></div>","PeriodicalId":18464,"journal":{"name":"Medecine et maladies infectieuses","volume":"50 8","pages":"Pages 738-741"},"PeriodicalIF":5.0,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.medmal.2020.07.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38149589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceptions and feelings of young girls regarding vaccination against papillomavirus","authors":"S. Dal Col Barthès,&nbsp;N. Dumoitier,&nbsp;K. Rudelle","doi":"10.1016/j.medmal.2020.02.007","DOIUrl":"10.1016/j.medmal.2020.02.007","url":null,"abstract":"<div><h3>Objective</h3><p>Cervical cancer can be avoided with smear screening, and since 2006 with vaccination against papillomavirus. Yet, vaccination coverage remains very low in France. We aimed to highlight the perceptions and feelings of young girls regarding papillomavirus vaccination, to initiate a discussion and find ways to promote this vaccination.</p></div><div><h3>Patients and methods</h3><p>Qualitative study with semi-directed interviews, until data saturation, and using grounded theory, with volunteer girls aged 11–14 years in a French department from September to December 2016.</p></div><div><h3>Results</h3><p>Thirty-four young girls were interviewed. Their opinion of anti-HPV vaccination was not negative. Knowledge of papillomavirus vaccination was better in those aged above 12 years, in urban areas, and in those vaccinated against hepatitis B. Young girls with parents working in the medical field seemed to be more involved in the vaccination process. Nevertheless, we observed a clear lack of knowledge or misbeliefs. Parents, especially mothers, were the most important source of information for girls. Family physicians played an essential role in the vaccination decision-making process.</p></div><div><h3>Conclusions</h3><p>Girls seem to be barely involved in the vaccination process. However, this vaccination is based on the young girl/parents/physician trio. All healthcare professionals should be trained so as to have a scientifically valid speech on vaccination. Family physicians play a central part. Comprehensive and adequate information should be provided to girls and parents.</p></div>","PeriodicalId":18464,"journal":{"name":"Medecine et maladies infectieuses","volume":"50 8","pages":"Pages 723-726"},"PeriodicalIF":5.0,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.medmal.2020.02.007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38252740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WITHDRAWN: Epidemiology and clinical analysis of the breakout of dengue fever in Zhangshu City, Jiangxi Province in 2019.","authors":"Jingen Wang, Qiubo Chen, Zhongbao Jiang, Xiaoju Li, Huiping Kuang, Ting Chen, Feng Liu, Wujuan Zhou, Yanxia Huang, Yong Luo, Jianfeng Rao, Weihua Ju, Li Wang, Xuping Peng, Zhicheng Zhang, Hongyi Chen","doi":"10.1016/j.medmal.2020.09.017","DOIUrl":"10.1016/j.medmal.2020.09.017","url":null,"abstract":"<p><p>This article has been withdrawn at the request of the author. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/our-business/policies/article-withdrawal.</p>","PeriodicalId":18464,"journal":{"name":"Medecine et maladies infectieuses","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2020-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38466841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of whole-cell versus acellular pertussis vaccine effectiveness in school clusters of pertussis, France, 2013","authors":"E. Belchior ,&nbsp;S. Guillot ,&nbsp;I. Poujol ,&nbsp;A. Thabuis ,&nbsp;L. Chouin ,&nbsp;M. Martel ,&nbsp;E. Delisle ,&nbsp;C. Six ,&nbsp;N. Guiso ,&nbsp;D. Lévy-Bruhl","doi":"10.1016/j.medmal.2020.07.004","DOIUrl":"10.1016/j.medmal.2020.07.004","url":null,"abstract":"<div><h3>Objectives and method</h3><p>We conducted a prospective study in 2013 to compare the whole-cell versus acellular pertussis vaccines effectiveness and duration of protection, following the occurrence of pertussis clusters.</p></div><div><h3>Results</h3><p>During seven school outbreaks, we identified 102 clinical pertussis cases, including 10 cases biologically confirmed by <em>Bordetella pertussis</em> specific PCR, among a cohort of 305 children in 2nd to 6th grade. The risk of pertussis when vaccinated with an acellular vaccine alone was 1.6 (RR<!--> <!-->=<!--> <!-->1.6; 95% CI<!--> <!-->=<!--> <!-->1.1–2.5) times higher than when vaccinated with a whole-cell vaccine or using a combined schedule.</p></div><div><h3>Conclusions</h3><p>The limited duration of protection conferred by the acellular vaccine reinforces the 2013 introduction of the pertussis booster at six years old.</p></div>","PeriodicalId":18464,"journal":{"name":"Medecine et maladies infectieuses","volume":"50 7","pages":"Pages 617-619"},"PeriodicalIF":5.0,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.medmal.2020.07.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38149587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fosfomycin, from susceptibility to resistance: Impact of the new guidelines on breakpoints","authors":"E. Farfour ,&nbsp;N. Degand ,&nbsp;E. Riverain ,&nbsp;V. Fihman ,&nbsp;C. Le Brun ,&nbsp;G. Péan de Ponfilly ,&nbsp;A. Muggeo ,&nbsp;A. Jousset ,&nbsp;C. Piau ,&nbsp;P. Lesprit","doi":"10.1016/j.medmal.2020.07.003","DOIUrl":"10.1016/j.medmal.2020.07.003","url":null,"abstract":"<div><p>The fosfomycin breakpoint using the disc diffusion method (DDM) changed in the 2019 CA-SFM/EUCAST guidelines v2 (24<!--> <!-->mm versus 19<!--> <!-->mm). We assessed its impact on categorization of Enterobacterales recovered from urine samples in emergency departments. A total of 7749 and 2348 strains were tested using the DDM and the broth microdilution method (BMD), respectively. The DDM with the 19-mm breakpoint was in accordance with the BMD. Using the 24-mm breakpoint, the overall rate of fosfomycin resistance in Enterobacterales increased by three-fold (5.6% vs 18.1%, <em>P</em> <!-->&lt;<!--> <!-->0.01) and reached 2.8% and 86.5% in <em>E. coli</em> and <em>K. pneumoniae</em>, respectively. French guidelines for the management of community-acquired UTI remain appropriate. The accuracy of the methods for routine fosfomycin susceptibility testing should be assessed. The role of fosfomycin in the treatment of documented CA-UTI due to Enterobacterales other than <em>E. coli</em> should be evaluated considering its rate of resistance and recent data reporting low accuracy.</p></div>","PeriodicalId":18464,"journal":{"name":"Medecine et maladies infectieuses","volume":"50 7","pages":"Pages 611-616"},"PeriodicalIF":5.0,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.medmal.2020.07.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38164419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}